The concern of generic rivalry has repeatedly loomed above copyright’s blockbuster drug, PDE5 Inhibitor, sparking questions about the outlook of similar drug ventures. While first years saw significant gains, the patent lapse has allowed the way for discounted substitutes, possibly lowering earnings and presenting a real risk for stakeholders loo